Registry study for newly diagnosed ITP or AIHA
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study is a registry that collects medical information from adults who are newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA), or who are starting a treatment called fosfamatinib. It can help doctors understand these conditions better and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older
- You were recently diagnosed with ITP or AIHA, or you are starting fosfamatinib
- You are willing to let the study collect and store your health data
- You do not oppose data collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.